{"nctId":"NCT00729430","briefTitle":"Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging","startDateStruct":{"date":"2008-08"},"conditions":["Myocardial Infarction","Death, Sudden, Cardiac"],"count":358,"armGroups":[{"label":"Omega-3 Fatty Acids","type":"EXPERIMENTAL","interventionNames":["Drug: Omega-3 Fatty Acids (Fish Oil Supplements)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Omega-3 Fatty Acids (Fish Oil Supplements)","otherNames":["Lovaza (GlaxoSmithKline)"]},{"name":"Placebo","otherNames":["Corn oil placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Experienced a heart attack in the 2 to 4 weeks before study entry\n* Lives in the greater Boston area or adjacent regions (within a 50-mile radius of Boston)\n\nExclusion Criteria:\n\n* Unable to undergo an MRI because of metallic implants (e.g., pacemakers, an implantable cardioverter defibrillator \\[AICD\\]) at time of study entry\n* Active cancer or any other terminal illness with an expected survival rate of less than 6 months after study entry\n* Significant kidney dysfunction with a glomerular filtration rate (GFR) of less than 60 mL/min in the 2 weeks before study entry\n* Inability to follow study procedures\n* Pregnant\n* Hemodynamic instability\n* Urgent clinical need for a pacemaker or AICD\n* Inaccessibility of medical records","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Effect of Omega-3 Fatty Acids on Adverse Left Ventricular Remodeling","description":"Measured as change in left ventricular end-systolic volume indexed to body surface area from baseline to post-treatment (6-months)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"16.6"},{"groupId":"OG001","value":"1.2","spread":"20.9"}]}]}]},{"type":"SECONDARY","title":"Effect of Omega-3 Fatty Acids on Non-Infarct Myocardial Fibrosis","description":"Measured as change in myocardial extracellular volume fraction of non-infarcted myocardium from baseline to post-treatment (6-months)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"14"},{"groupId":"OG001","value":"3.4","spread":"15"}]}]}]},{"type":"SECONDARY","title":"Effect of Omega-3 Fatty Acids on Left Ventricular Ejection Fraction","description":"Measured as change in left ventricular ejection fraction from baseline to post-treatment (6-months)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"11"},{"groupId":"OG001","value":"2.1","spread":"12"}]}]}]},{"type":"SECONDARY","title":"Effect of Omega-3 Fatty Acids on Infarct Size","description":"Measured as change in infarct size from baseline to post-treatment (6-months)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.8","spread":"39.9"},{"groupId":"OG001","value":"-1.9","spread":"57.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":180},"commonTop":["Nausea","Fishy Taste in Mouth"]}}}